- Conditions
- Glaucoma, Glaucoma Following Surgery
- Interventions
- Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)
- Device
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glaucoma
- Interventions
- Heidelberg Spectralis OCT
- Device
- Lead sponsor
- Heidelberg Engineering GmbH
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2023
- U.S. locations
- 8
- States / cities
- La Jolla, California • Santa Monica, California • Santa Rosa, California + 5 more
- Conditions
- Healthy
- Interventions
- Not listed
- Lead sponsor
- Heidelberg Engineering GmbH
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
- Interventions
- Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
- Other · Diagnostic Test · Genetic
- Lead sponsor
- University of Rhode Island
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
- Conditions
- Geographic Atrophy
- Interventions
- Adaptive Optics Scanning Light Ophthalmoscopy, Microperimetry, Optical Coherence Tomography
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Retinal Layer Separation
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- Heidelberg Engineering GmbH
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glaucoma, Open-Angle
- Interventions
- Standard Automatic Perimetry Humphrey Field Analyzer, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT)
- Diagnostic Test
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Interventions
- Optical Coherence Tomography Angiography (OCTA) Imaging, Noninvasive Retinal Amyloid Imaging (NRAI)
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Ocular Tumor
- Interventions
- Intalight Dream OCT, Heidelberg Spectralis OCT
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
- Interventions
- Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
- Device
- Lead sponsor
- Notal Vision Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Edema, Central Retinal Vein Occlusion
- Interventions
- Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
- Drug
- Lead sponsor
- Valley Retina Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more
- Conditions
- Retinal Vascular, Normal Eyes
- Interventions
- OCT Angiography, Color Fundus Photography, Optical Coherence Tomography
- Device
- Lead sponsor
- Heidelberg Engineering GmbH
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Retinal Vascular, Normal Eyes
- Interventions
- OCT Angiography, Color Fundus Photography, Optical Coherence Tomography
- Device
- Lead sponsor
- Heidelberg Engineering GmbH
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Diabetic Retinal Disease
- Interventions
- Anti-Vascular Endothelial Growth Factor
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Augusta, Georgia • Boston, Massachusetts • Detroit, Michigan + 3 more